Dermata Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
DRMA$0.76+0.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| June 30, 2025 | December 31, 2024 | |
|---|---|---|
| (unaudited) | ||
| Assets: | ||
| Cash and cash equivalents | $6,480,930 | $3,161,570 |
| Prepaid expenses and other current assets | 159,586 | 372,318 |
| Total assets | $6,640,516 | $3,533,888 |
| Liabilities and Stockholders’ Equity: | ||
| Liabilities: | ||
| Accounts payable | $413,687 | $808,011 |
| Accrued and other current liabilities | 612,578 | 1,164,783 |
| Total liabilities | 1,026,265 | 1,972,794 |
| Commitments and Contingencies (see Note 6) | - | - |
| Stockholders’ Equity: | ||
| Common Stock, par value $0.0001 per share, 250,000,000 shares authorized; 637,757 shares issued and outstanding as of June 30, 2025; 251,725 shares issued and outstanding as of December 31, 2024 | 64 | 25 |
| Additional paid-in capital | 75,294,206 | 67,236,408 |
| Accumulated deficit | (69,680,019) | (65,675,339) |
| Total stockholders’ equity | 5,614,251 | 1,561,094 |
| Total liabilities and stockholders’ equity | $6,640,516 | $3,533,888 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.